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Amburana cearensis is a medicinal plant known as “cumaru”. It is used in Northeast Brazil in the treatment 
of respiratory diseases. This was a randomized, double-blind, placebo-controlled study, with the aim of 
evaluating the efficacy and safety of cumaru syrup as complementary therapy in mild persistent asthma. 
The study consisted of 3 phases, pre-treatment, treatment and post-treatment. The primary efficacy 
outcome was comparison of the changes reported by patients of the cumaru and placebo groups after 
treatment, using the “Asthma Quality of Life Questionnaire” (AQLQ). The secondary outcome was the 
effect of cumaru syrup on lung function based on spirometry. The results showed that in the cumaru 
group, the proportion of patients who had global improvement in asthma symptoms was significantly 
greater (61.90%, P=0.0009) than in the placebo group (9.52%). Only the spirometric parameters Forced 
Vital Capacity (FVC) and Forced Expiratory Volume in 1 second (FEV1) showed significant intergroup 
differences in post-treatment (P<0.05). The hematological and serum chemistry tests performed in the 
pre-treatment and post-treatment showed no statistically significant differences (P>0.05). Adverse events 
were reported by 3 patients (14.29%) in the cumaru group and 3 patients (14.29%) in the placebo group. 
All adverse events were considered non-serious and mild.
Uniterms: Amburana cearensis/phytoterapy. Cumaru syrup/efficacy. Asthma/treatment. 
Amburana cearensis é uma planta medicinal conhecida como “cumaru”. No Nordeste do Brasil é usada no 
tratamento de doenças respiratórias. Este é um estudo randomizado, duplo-cego e controlado por placebo, 
com o objetivo de avaliar a eficácia e segurança do xarope de cumaru como terapia complementar da 
asma persistente leve. O estudo consistiu de três fases, pré-tratamento, tratamento e pós-tratamento. A 
variável primária para determinação da eficácia foi a comparação das mudanças referidas pelos pacientes 
dos grupos cumaru e placebo após o tratamento, usando o “Questionário sobre Qualidade de Vida na 
Asma” (QQVA). A variável secundária foi o efeito do xarope de cumaru na função pulmonar baseado na 
espirometria. Os resultados mostraram que no grupo cumaru, a proporção de pacientes com melhora global 
dos sintomas da asma foi significativamente maior (61,90%, P=0.0009) que no grupo placebo (9,52%). 
Somente os parâmetros espirométricos, capacidade vital forçada (CVF) e volume expiratório forçado no 
primeiro segundo (VEF1), mostraram diferença intergrupo significtivas no pós-tratamento (P<0.05). Os 
testes hematológicos e do soro realizados no pré-tratamento e pós-tratamento não mostraram diferenças 
estatisticamente significativas (P>0.05). Eventos adversos foram reportados por 3 pacientes (14,29%) 
no grupo cumaru e 3 (14,29%) no grupo placebo. Todos os eventos adversos foram não sérios e leves.
Unitermos: Amburana cearensis/fitoterapia. Xarope de Cumaru/eficácia. Asma/tratamento. 
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INTRODUCTION
Asthma is a chronic inflammatory disease and a 
global health problem affecting around 300 million in-
dividuals of all ages, ethnic groups and countries. It is 
estimated that around 250,000 people die prematurely 
each year as a result of asthma (Bousquet et al., 2010). 
Several classes of medicines are indicated in the treatment 
of asthma (Patel et al., 2010; GINA, 2008; Gerald et al., 
2008). On the other hand, the use of complementary and 
alternative medicine is becoming more common, mainly 
in the last decades (Metcalfe et al., 2010; Cunha et al., 
2011). Herbal products, even though in prevalent use, are 
of uncertain value in the treatment of asthma, and only 
randomized controlled trials can truly determine efficacy 
(Passalacqua et al., 2005; Mega et al., 2011).
Amburana cearensis A. C. Smith, Fagaceae, is a 
medicinal plant commonly known as “cumaru,” which 
is used in Northeast Brazil as an anti-inflammatory and 
spasmolytic medication and also in the treatment of re-
spiratory tract diseases (Leal et al., 2003a). A toxicologi-
cal study of the hydroalcoholic extract of A. cearensis in 
rats, administered sub-chronically and during pregnancy, 
showed that an oral dose of 500 mg/kg did not cause toxic 
effects, suggesting that it could be used with reasonable 
safety in pharmaceutical preparations such as “cumaru 
syrup” (Leal et al., 2003b).
Pre-clinical studies have examined the relaxing 
action of the hydroalcoholic extract of A. cearensis in 
tracheal smooth muscle pre-contracted by carbachol, 
histamine and KCl, demonstrating that the hydroalco-
holic extract and chemical constituents of A. cearensis 
have anti-inflammatory as well as smooth muscle relax-
ant activities, justifying traditional uses of the plant as 
a bronchodilator in the treatment of respiratory tract 
diseases (Leal et al., 2003a, 2010). Anti-inflammatory 
effects can be explained, at least in part, by the ability 
of these compounds to reduce neutrophil degranulation, 
myeloperoxidase activity, as well as TNF-alpha secretion 
(Leal et al., 2009).
The large-scale use of wild A. cearensis as a me-
dicinal plant, and in the formulation of cumaru syrup by 
Governmental Programs of Phytotherapy, in Northeast 
Brazil, and by the local pharmaceutical industry, justifies 
a study in humans. Cumaru syrup has a low cost and has 
been widely used indiscriminately by people with asthma, 
but its efficacy has yet to be proven through clinical trials. 
Thus, the aim of the present study was to investigate the 
therapeutic efficacy and safety of cumaru syrup as comple-
mentary therapy in mild persistent asthma.
METHODS
Patients
This study was conducted in accordance with the 
Declaration of Helsinki and the protocol was approved by 
the Ethics Committee of the Federal University of Ceará, 
in Fortaleza, Brazil, with registration number 169/07. All 
patients gave their signed informed consent and were free 
to withdraw from the trial at any time.
Patients were selected at the outpatient clinics of 
the Doctor Carlos Alberto Gomes Studart Hospital and 
Walter Cantídio University Hospital, both references in 
the treatment of pulmonary diseases. These patients had 
mild persistent asthma controlled and were enrolled in 
the National Asthma Control Program promoted by the 
Ministry of Health in each institution. The patients were 
recruited for the Clinical Pharmacology Unit and submit-
ted to a health evaluation by a doctor and physiotherapist.
The criteria for inclusion in the study were as fol-
lows: male or female patients, aged 18 years and older, 
confirmed diagnosis of mild persistent asthma controlled 
in accordance with the criteria of Global Initiative for 
Asthma - GINA (GINA, 2008), and currently receiving 
inhaled corticosteroid medication at a total daily dose 
of 250-750 µg beclomethasone dipropionate regularly 
by at least three weeks, combined or not with inhaled 
beta-2-adrenergic agonist (salbutamol) for short times. 
Exclusion criteria included hypersensitivity to the study 
drug, addiction to drugs and smoking, use of experimental 
drugs in the previous 6 months, laboratory tests showing 
clinical abnormalities, untreated illnesses, pregnancy, and 
breast-feeding.
Female patients of child-bearing potential were 
included after confirmation of a negative pregnancy test 
(β-subunit of human chorionic gonadotropin - HCG), 
and were recommended to use highly effective methods 
of birth control contraceptives during the study, such as 
oral contraceptive and condom, intra-uterine device (IUD) 
and condom or diaphragm with spermicide and condom.
Study design
This was a randomized, double-blind, placebo-
controlled study, with the aim of evaluating the efficacy of 
cumaru syrup as complementary therapy in mild persistent 
asthma. The study consisted of 3 phases, pre-treatment, 
treatment and post-treatment.
During pre-treatment, the patients signed an in-
formed consent form. Physical examination and electro-
cardiogram were performed and the diagnosis of mild 
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persistent asthma was confirmed. We also monitored 
body mass index (BMI), systolic blood pressure, diastolic 
blood pressure and heart rate after 30 min of rest in sitting 
position. Spirometry was measured (COSMED Pony FX) 
and the questionnaire was administered: “Juniper Asthma 
Quality of Life Questionnaire” (AQLQ) (Juniper et al., 
1992). The treatment phase consisted of randomization 
and administration three times a day for fifteen days of 
15.0 mL of cumaru syrup or placebo. Randomization and 
distribution of the cumaru syrup were performed by a 
pharmacist who has not evaluated the effectiveness of the 
product in the patients. The blind code was broken after 
the study for analysis of efficacy variables by a statistician. 
The post-treatment consisted of evaluation of the patient 
following cumaru syrup or placebo administration, includ-
ing spirometry and administration of AQLQ.
Cumaru syrup
Cumaru syrup is produced by the Scholl Pharmacy 
Laboratory of the Federal University of Ceará, located in 
Fortaleza, Brazil. Trunk bark of wild adult A. cearensis 
was collected in Fortaleza, Ceará State, Northeast Brazil. 
Voucher specimens (no. 837 and 847) were deposited at 
the Prisco Bezerra Herbarium, Department of Biology of 
the Federal University of Ceará.
The collected fresh plant material (trunk bark) was 
dried and immediately ground and submitted to extraction 
with water/ethanol (4:1), by mechanical stirring at room 
temperature (22 oC) for 24 h. Ethanol was evaporated 
away and the volume adjusted to the concentration needed, 
just before use. The yield was 12%, based on solid resi-
dues. The hydroalcoholic extract obtained was analyzed 
by HPLC according the method previously described 
(Canuto, Silveira, 2006; Canuto, 2007). The chemical 
constituents (vanillic acid, coumarin, protocatechuic acid 
and amburoside A) were isolated as described in a previous 
work (Canuto, Silveira, 2010).
Cumaru syrup contains 100 mL of simple essential 
syrup and 5% hydroalcoholic extract of A. cearensis, 
containing 0.15 mg/mL coumarin. The placebo was com-
posed of only the simple essential syrup. The product 
characteristics were: slightly cloudy and yellowish color; 
sweet aroma; and viscosity, density and pH respectively 
43.8 cP, 1.2379 g/mL and 6.0 for cumaru syrup and 44.0 
cP, 1.2410 g/mL and 6.3 for placebo.
Primary and secondary efficacy variables
The primary outcome was comparisons of the 
changes reported by patients of the cumaru and placebo 
groups after the treatment, by questionnaire “Asthma 
Quality of Life Questionnaire” (AQLQ).
This instrument is an asthma-specific questionnaire 
with 32 items, which provides an Overall Summary Index 
and assesses four domains of health-related quality of life, 
namely symptoms, activity limitations, environmental 
stimulus and emotional function, during the 2 weeks of 
treatment (Juniper et al., 1992). The response options for 
each of the 32 items are on a 7-point scale, ranging from 
1 (totally limited) to 7 (not at all limited). AQLQ has been 
shown to be sensitive to change in health-related quality of 
life. A change in score of 0.5 points has been determined to 
be the minimally important difference (Juniper et al., 1994).
The secondary outcome was the effect of cumaru 
syrup on lung function based on spirometry. Forced vi-
tal capacity (FVC), peak expiratory flow (PEF), forced 
expiratory volume in 1 second (FEV1), forced expiratory 
flow between 25 and 75% (FEF 25-75%) and the relation 
(FEV1/FVC) were measured in pre-treatment and post-
treatment.
Safety and tolerability
Patients in the cumaru and placebo groups were 
asked to record any adverse events in their diary during the 
treatment. Adverse events were mapped to preferred terms 
and body systems and coded using the Adverse Reaction 
Terminology Dictionary of the World Health Organization 
(WHO, 2004).
Hematological and serum chemistry tests were 
evaluated in pre-treatment and post-treatment in the 
cumaru and placebo groups. Tests were performed for 
determination of hemoglobin, red blood cells, hematocrit, 
platelets, leukocytes, lymphocytes, basophils, eosinophils, 
monocytes, neutrophils, prothrombin time (PT), activated 
partial thromboplastin time (APTT), glucose, creatinine, 
urea, serum glutamic oxaloacetic transaminase (aspartate 
aminotransferase – AST), and serum glutamic pyruvic 
transaminase (alanine aminotransferase – ALT), as well 
as HCG β-subunit in female patients of child-bearing 
potential.
Analyses were performed at a local accredited labo-
ratory. When values for a given sample were outside the 
normal range, the analysis was repeated to confirm the 
findings. Abnormal values were recorded by the investiga-
tor on the case report form and an assessment was made 
of their likely etiology.
Statistical analysis
The quantitative variables were initially analyzed 
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by the Kolmogorov-Smirnov test to verify the normality 
of distribution. For descriptive statistics, the mean and 
standard deviation (parametric data) or median, inter-
quartile range and minimum and maximum values (non-
parametric data) were calculated. Comparisons between 
groups (placebo versus cumaru) in each phase were made 
using unpaired t test (parametric data) or Mann-Whitney 
U test (nonparametric variables). Comparisons between 
the two phases (pre-treatment and post-treatment) in the 
same group were performed using paired t test (parametric 
data) or Wilcoxon test (nonparametric variables). Nomi-
nal qualitative variables were expressed as absolute and 
relative frequency and analyzed by Fisher’s exact test. 
Ordinal qualitative variables were expressed as median, 
interquartile range and minimum and maximum values 
and analyzed by the Mann-Whitney U test. The signifi-
cance level was set at 0.05 (5%) and a P-value less than 
0.05 was accepted as statistically significant. The statistical 
software GraphPad Prism® version 5.00 was used for data 
processing and designing of the graphs.
RESULTS
Of the 67 patients initially evaluated, only 47 met the 
inclusion criteria. Twenty-five patients were randomized 
to receive cumaru syrup and 22 to receive placebo. Four 
patients in the cumaru and one in the placebo group were 
lost to follow-up and so were withdrawn from the trial 
due to a deviation from the experimental protocol. Patient 
demographics and pre-treatment characteristics were very 
similar for the cumaru and placebo groups, except for the 
age, which was higher in the cumaru group, showing a 
statistically significant difference (P=0.0054) (Table I).
The mean total individual AQLQ scores of the 
placebo and cumaru groups in the pre-treatment and 
post-treatment phases are shown in Table II. A statistically 
significant association was observed between the type of 
treatment employed and the global improvement in mild 
persistent asthma. In the cumaru group, the proportion of 
patients who had global improvement in asthma was sig-
nificantly greater (61.90%, P=0.0009) than in the placebo 
group (9.52%), with a relative risk of 6.50 (95% confi-
dence interval: 1.67 to 25.34), which means that patients 
treated with cumaru syrup were 6.5 times more likely to 
have an improvement in their asthma clinical status than 
the patients treated with placebo (Table III).
In the evaluation of lung function, only the spiromet-
ric parameters forced vital capacity (FVC) and expiratory 
volume in 1 second (FEV1), both in liters, showed inter-
group significance in post-treatment (P<0.05). However, 
these changes were not considered clinically significant, 
because it existed prior to treatment, although no statistical 
significance (Table IV).
The hematological and serum chemistry tests per-
formed in pre-treatment and post-treatment showed no 
statistically significant differences (P>0.05) (Table V). 
Adverse events were reported by three patients (14.29%) 
in the cumaru group and three patients (14.29%) in the pla-
cebo group. The adverse events were dizziness, headache 
and nausea. There were no significant differences between 
TABLE I - Demographics and pre-treatment characteristics for patients of Placebo and Cumaru groups. Data expressed as relative 
frequency or mean ± standard deviation
Characteristic Placebo group Cumaru group
Number of patients 21 21
Sex Male = 5/21 (23.8%) 
Female = 16/21 (76.1%)
Male = 3/21 (14.2%) 
Female = 18/21 (85.7%)
Age (years) 37.2 ± 10.3 46.6 ± 10.3*
BMI (kg/m2) 26.3 ± 4.1 27.2 ± 4.3
Systolic blood pressure (mmHg) 117.5 ± 16.8 121.1 ± 15.9
Diastolic blood pressure (mmHg) 82.2 ± 9.5 82.3 ± 8.8
Mean blood pressure (mmHg) 93.9 ± 11.3 95.3 ± 10.7
FEV1 (%) 82.9 ± 17.3 83.4 ± 25.0
PEF (%) 71.4 ± 18.9 73.5 ± 26.3
Use of rescue medication 20/21 (95.2%) 19/21 (90.4%)
Mean total AQLQ score 4.5±1.1 4.3±1.1
*P=0.0054 versus placebo group.
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the proportion of patients who had adverse events in the 
cumaru and the placebo groups, demonstrating safety in 
the use of cumaru syrup. All adverse events were consid-
ered non-serious and of mild intensity. No patient was 
withdrawn from the study due to adverse events.
DISCUSSION
This randomized study evaluated the efficacy and 
safety of cumaru syrup as complementary therapy in mild 
persistent asthma. Based on a placebo-controlled and dou-
ble-blind design, it was observed that this phytotherapeutic 
product was safe and caused a significant improvement in 
the patients with mild persistent asthma.
Pre-clinical studies have shown that the hydroalco-
holic extract of A. cearensis has anti-inflammatory and 
smooth muscle relaxant activities, justifying traditional 
uses of the plant as bronchodilator in the treatment of re-
spiratory tract diseases (Leal et al., 2003a). Furthermore, 
previous studies reported antinociceptive and antioxidant 
properties of the hydroalcoholic extract and chemical con-
stituents of this plant (Leal et al., 2009; Leal et al., 2005).
Several compounds have been isolated from the 
trunk bark of A. cearensis, including coumarin (1,2-ben-
TABLE II - AQLQ domains scores and AQLQ global score for Placebo and Cumaru groups in pre-treatment and post-treatment 
phases, expressed as mean ± standard deviation
Domain
Pre-treatment Post-treatment
Placebo group Cumaru group P value1 Placebo group Cumaru group P value1
Symptoms 4.94 ± 1.38 4.57 ± 1.38 0.3966 4.83 ± 1.20 6.21 ± 0.60† < 0.0001
Activity limitations 4.12 ± 0.94 4.04 ± 1.13 0.7986 4.38 ± 1.01 5.86 ± 0.78† < 0.0001
Environment stimulus 3.98 ± 1.49 3.71 ± 1.45 0.5674 4.51 ± 1.99 5.61 ± 1.35† 0.0431
Emotional function 4.78 ± 1.55 4.75 ± 1.72 0.9552 4.99 ± 1.48 6.25 ± 1.03‡ 0.0028
Mean total AQLQ score 4.51 ± 1.14 4.31 ± 1.20 0.5770 4.66 ± 1.13 6.02 ± 0.74† < 0.0001
1Intergroup significance. †P<0.0001, ‡P=0.0003 in relation to pre-treatment phase in the same group.
TABLE III - Global improvement of mild persistent asthma 
observed in Cumaru and Placebo groups, which was defined as 
an increase of at least 0.5 in all AQLQ domains, as well as in 
the AQLQ global score
Group Global improvement of asthma Total
Presence Absence
Cumaru 13 (61.90%)† 8 21
Placebo 2 (9.52%) 19 21
Total 15 27 42
†P = 0.0009 (Fisher’s exact test).
TABLE IV - Evaluation of lung function in the patients of Placebo and Cumaru groups, according to spirometric parameters. The 




Placebo Cumaru P value1 Placebo Cumaru P value1
FVC (%) 98.28 ± 10.99 99.37 ± 23.90 0.85 102.37 ± 11.66 98.40 ± 24.16 0.50
FVC (L) 3.30 ± 0.51 2.92 ± 0.96 0.12 3.43 ± 0.69 2.91 ± 0.90 0.04
PEF (%) 71.46 ± 18.95 73.53 ± 26.32 0.77 74.50 ± 19.04 76.05 ± 31.11 0.84
PEF (L/s) 4.7 ± 1.09 4.47 ± 1.61 0.50 5.22 ± 1.16 4.54 ± 1.82 0.16
FEV1 (%) 82.97 ± 17.35 83.45 ± 25.02 0.94 86.04 ± 17.32 82.30 ± 23.09 0.55
FEV1 (L) 2.33 ± 0.42 2.05 ± 0.73 0.13 2.42 ± 0.50 2.01 ± 0.66 0.02
FEF 25–75% (%) 62.73 ± 30.52 60.87 ± 31.34 0.84 64.12 ± 29.22 59.62 ± 31.92 0.63
FEF 25–75% (L/s) 2.05 ± 1.05 1.62 ± 0.84 0.15 2.06 ± 0.95 1.57 ± 0.82 0.08
FEV1/FVC 84.40 ± 16.49 83.60 ± 14.85 0.86 84.48 ± 16.61 83.85 ± 13.70 0.89
1Intergroup significance.
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zopyrone), its main constituent, plus isokaempferide 
(4’,5,7-trihydroxyflavone), fisetin (3,5,3’,4’-tetrahydroxy-
flavone) and alfalone (6-hydroxy-4’,7-dimethoxyisofla-
vone) (Canuto, Silveira, 2006). From the seeds of this 
plant, a Bowman-Birk trypsin inhibitor was isolated and 
purified. It was demonstrated that this inhibitor prolongs 
the blood clotting time of the contact phase activation 
pathway by inhibition of FXIIa (Tanaka et al., 1997).
Asthma is a common chronic inflammatory disease. 
Asthma cannot be cured, but appropriate management can 
control the disorder and enable people to enjoy a good 
quality of life. Identifying and treating impaired health-
related quality of life is now recognized as an important 
component of asthma management (Juniper et al., 2004).
The primary outcome of the study was the score 
on the “Asthma Quality of Life Questionnaire” (AQLQ). 
With an individual patient change in AQLQ score of 0.5 
signifying a clinically relevant change in health status 
(Guyatt et al., 1998), 61.90% of the subjects improved 
with cumaru syrup, and 9.52% improved with placebo. 
The secondary outcome of the study was lung function 
according to spirometry, where only FVC (L) and FEV1 
(L) showed intergroup significance in post-treatment.
International guidelines state that treatments should 
not only improve asthma clinical status, and thus reduce 
the risk of exacerbations and possibly airway remodel-
ling, but should also enable patients to feel and function 
better in their day-to-day lives (Juniper et al., 2004). 
Asthma-specific quality of life questionnaires have been 
developed and validated so that this aspect of patient 
management can be accurately measured and treatment 
effectiveness assessed. These questionnaires are now used 
in both clinical trials and clinical practice alongside the 
more traditional clinical measures of airway status, such 
as airway caliber, symptoms and markers of inflammation 
(Juniper et al., 2002).
TABLE V - Results of hematological and serum chemistry tests for Placebo and Cumaru groups in pre-treatment and post-treatment 
phases. Data expressed as mean ± standard deviation or median and interquartile range
Parameters
Placebo group Cumaru group
Reference range 
Pre-treatment Post-treatment Pre-treatment Post-treatment
Hemoglobin 13.75±1.28 13.69±1.08 13.47±0.73 13.60±1.06 Male: 12.8–17.8 g/dL
Female:11.5–16.4 g/dL
Red blood cells 4.70±0.39 4.64±0.32 4.68±0.26 4.70±0.36 Male: 4.5–6.1 million/mm3
Female: 4.1–5.3million/mm3
Hematocrit 41.53±3.07 41.05±2.75 41.33±2.35 41.27±3.05 Male: 40.0%–54.0%
Female: 36.0%–48.0%
Platelets 267.85±50.59 268.76±41.04 279.61±61.49 268.55±50.64 150–450 103/mm3
Leukocytes 7.34±2.38 6.84±2.74 7.10±1.55 7.15±1.58 3.6–11 103/mm3
Lymphocytes 29.76±7.12 28.66±7.85 27.61±6.02 27.11±4.41 20–50/mm3
Basophils 0.00 (0.00–1.00) 1.00 (0.00–1.00) 0.00 (0.00–1.00) 0.00 (0.00–1.00) 0–3/mm3
Eosinophils 4.00 (3.00–6.00) 4.00 (2.00–6.00) 3.00 (2.00–6.00) 2.50 (2.00–5.00) 1–6/mm3
Monocytes 7.42±2.48 7.57±1.85 8.05±1.86 8.66±2.00 2–10/mm3
Neutrophils 57.42±8.38 58.38±9.80 59.05±5.37 59.16±5.58 45–70/mm3
PT 108.11±14.89 107.91±12.48 106.50±9.74 107.61±27.37 ≥ 70%
APTT 0.98±0.17 0.98±0.12 0.96±0.11 0.94±0.10 ≤ 1.20
Glucose 81.42±11.46 84.71±13.42 84.33±14.9 87.38±15.77 70–99 mg/dL
Creatinine 0.75±0.16 0.73±0.14 0.73±0.12 0.69±0.14 0.6–1.2 mg/dL
Urea 26.56±6.29 24.59±6.17 27.03±6.88 24.76±6.11 10–50 mg/dL
AST 24.29±9.13 23.37±8.07 19.68±3.79 20.17±3.99 Male: ≤ 38 U/L
Female: ≤ 32 U/L
ALT 24.16±13.59 22.31±10.16 19.64±9.04 19.16±8.74 Male: ≤ 41 U/L
Female: ≤ 31 U/L
For all parameters analyzed, no significant differences (P>0.05) were found between Placebo and Cumaru groups in each phase 
or between pre-treatment and post-treatment phases in the same group.
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In another study that evaluated the effectiveness of 
the herbal medicine called AKLI, which contains the phy-
tochemical component of Picrorrhiza kurroa, and extracts 
of Zingiber officinale and Ginkgo biloba, similar results as 
in the present study were also obtained; the efficacy was 
satisfactory in accordance with the AQLQ, but no statis-
tically significant changes were found in lung function 
by spirometry data (Thomas et al., 2007). Other studies 
also demonstrated the effectiveness of herbal medicines 
as complementary therapy in asthma (Kelly-Pieper et al., 
2009; Wong et al., 2009; Zhou et al., 2009).
The clinical examinations, physical evaluation and 
laboratory tests performed before and after the research 
did not show evidence of toxicity in the several organs and 
systems assessed. The adverse events reported for cumaru 
group and placebo group were all classified as non-serious 
and mild. These events did not result in any withdrawal 
from the trial. Preclinical toxicology studies in rats have 
shown that a hydroalcoholic extract of A. cearensis ad-
ministered sub-chronically and during pregnancy in an 
oral dose of 500 mg/kg, did not cause toxic effects and did 
not modify the biochemical and hematological profiles of 
the animals after treatment, indicating that extracts of A. 
cearensis can be used with reasonable safety in pharma-
ceutical preparations such as cumaru syrup. The clinical 
toxicology study of a herbal medicine formulation of Tor-
resea cearensis (cumaru) in healthy volunteers concluded 
that clinical, electrocardiography and laboratory tests did 
not show any evidence of toxic signs in the various organs 
and systems studied (Soares et al., 2007).
There were difficulties in comparing the results 
obtained in other studies due to the existence of only 
preclinical studies of efficacy with A. cearensis. This 
clinical trial is the first study to evaluate the efficacy and 
safety of cumaru syrup in the treatment of mild persistent 
asthma in humans. It is concluded that this phytothera-
peutic medication showed a significant beneficial ef-
fect, representing an alternative for the complementary 
therapy of asthma.
Finally, we suggest conducting further studies with 
larger samples of volunteers and period of prolonged treat-
ment to observe the efficacy, toxicology and safety of the 
cumaru syrup because asthma is a chronic inflammatory 
disease. We consider the difficulties encountered in ef-
ficacy studies, lack of follow-up, high cost, accessibility 
of patients, among other things. After confirming their 
therapeutic efficacy and safety through clinical trials, 
phytotherapeutic medicines can be of great economic, 
medicinal, and social importance, when produced with 
rigorous quality control and used properly by patients.
REFERENCES
BATEMAN, E.D.; HURD, S.S.; BARNES, P.J.; BOUSQUET, 
J.; DRAZEN, J.M.; FITZGERALD, M. Global strategy 
for asthma management and prevention. GINA Executive 
Summary. Eur. Respir. J., v.31, n.1, p.143-178, 2008.
BOUSQUET, J.; MANTZOURANIS, E.; CRUZ, A.A.; AÏT-
KHALED, N.; BAENA-CAGNANI, C.E.; BLEECKER, 
E.R. Uniform definition of asthma severity, control, and 
exacerbations: Document presented for the World Health 
Organization Consultation on Severe Asthma. J Allergy 
Clin. Immunol., v.126, n.5, p.926-938, 2010.
CANUTO, K.M. Chemical aspects of interdisciplinary study 
(chemistry, pharmacology, agronomy) from A. cearensis 
A. C. Smith, 2007. 303p. [Thesis of PhD degree. Faculty 
of Medicine, Federal University of Ceará].
CANUTO, K.M.; SILVEIRA, E.R. Chemical constituents of 
trunk bark of Amburana cearensis A. C. Smith. Quím. Nova, 
v.29, n.6, p.1241-1243, 2006.
CANUTO, K.M.; SILVEIRA, E.R. Estudo fitoquímico de 
espécimes cultivadas de cumaru (Amburana cearensis A. 
C. SMITH). Quím. Nova, v.33, n.3, p.662-666, 2010.
CUNHA, G.H.; FECHINE, F.V.; SANTOS, L.K.X.; PONTES, 
A.V.; OLIVEIRA, J.C.; MORAES, M.O. Efficacy of the 
tincture of jalapa in the treatment of functional constipation: 
a double-blind, randomized, placebo-controlled study. 
Contemp. Clin. Trials, v.32, n.2, p.153-159, 2011.
GERALD, L.B.; MCCLURE, L.A.; HARRINGTON, K.F.; 
MANGAN, J.M.; GIBSON, L.; ATCHISON, J.; GRAD, 
R. Design of the supervised asthma therapy study: 
Implemeting an adherence intervention in urban elementary 
schools. Contemp. Clin. Trials, v.29, n.2, p.304-310, 2008.
GUYATT, G.H.; JUNIPER, E.F.; WALTER, S.D.; GRIFFITHS, 
L.E.; GOLDSTEIN, R.S. Interpreting treatment effects in 
randomized trials. BMJ, v.316, p.690-693, 1998.
JUNIPER, E.F.; GUYATT, G.H.; EPSTEIN, R.S.; FERRIE, P.J.; 
JAESCHKE, R.; HILLER, T.K. Evaluation of impairment 
of health related quality of life in asthma: development of 
a questionnaire for use in clinical trials. Thorax, v.47, n.2, 
p.76-83, 1992.
E. M. Carvalho, G. H. Cunha, F. V. Fechine, C. R. A. Uchôa, M. O. Moraes Filho, F. A. F. Bezerra, M. E. A. Moraes636
JUNIPER, E.F.; GUYATT, G.H.; WILLAN, A.; GRIFFITH, 
L.E. Determining a minimal important change in a disease-
specific quality of life questionnaire. J. Clin. Epidemiol., 
v.47, n.1, p.81-87, 1994.
JUNIPER, E.F.;  PRINCE, D.B.;  STAMPONE, P.A.; 
CREEMERS, J.P.; MOL, S.J.; FIREMAN, P. Clinically 
important improvements in asthma-specific quality of life, 
but no difference in conventional clinical indexes in patients 
changed from conventional beclomethasone dipropionate 
to approximately half the dose of extrafine beclomethasone 
dipropionate. Chest, v.121, n.6, p.1824-1832, 2002.
JUNIPER, E.F.; WISNIEWSKI, M.E.; COX, F.M.; EMMETT, 
A.H.; NIELSEN, K.E.; O’BYRNE, P.M. Relationship 
between quality of life and clinical status in asthma: a factor 
analysis. Eur. Respir. J., v.23, n.2, p.287-291, 2004.
KELLY-PIEPER, K.; PATIL, S.P.; BUSSE, P.; YANG, N.; 
SAMPSON, H.; LI, X.M.; WISNIVESKY, J.P.; KATTAN, 
M. Safety and tolerability of an antiasthma herbal Formula 
(ASHMI) in adult subjects with asthma: a randomized, 
double-blinded, placebo-controlled, dose-escalation phase 
I study. J. Altern. Complement. Med., v.15, n.7, p.735-743, 
2009.
LEAL, L.K.; CANUTO, K.M.; SILVA COSTA, K.C.; NOBRE-
JÚNIOR, H.V.; VASCONCELOS, S.M.; SILVEIRA, E.R.; 
FERREIRA, M.V.; FONTENELE, J.B.; ANDRADE, G.M.; 
BARROS VIANA, G.S. Effects of amburoside A and 
isokaempferide, polyphenols from Amburana cearensis, 
on rodent inflammatory processes and myeloperoxidase 
activity in human neutrophils. Basic. Clin. Pharmacol. 
Toxicol., v.104, n.3, p.198-205, 2009.
LEAL, L.K.; NECHIO, M.; SILVEIRA, E.R.; CANUTO, K.M.; 
FONTENELE, J.B.; RIBEIRO, R.A.; VIANA, G.S. Anti-
inflammatory and smooth muscle relaxant activities of the 
hydroalcoholic extract and chemical constituents from 
Amburana cearensis. A C Smith. Phytother. Res., v.17, n.4, 
p.335-340, 2003a.
LEAL, L.K.; NOBRE JÚNIOR, H.V.; CUNHA, G.M.; 
MORAES, M.O.; PESSOA, C.; OLIVEIRA, R.A.; 
SILVEIRA, E.R.; CANUTO, K.M.; VIANA, G.S. 
Amburoside A, a glucoside from Amburana cearensis, 
protects mesencephalic cells against 6-hydroxydopamine-
induced neurotoxicity. Neurosci. Lett., v.388, n.2, p.86-90, 
2005.
LEAL, L.K.A.M.; OLIVEIRA, F.G.; FONTENELE, J.B.; 
FERREIRA, M.A.D.; VIANA, G.S.B. Toxicological study 
of the hydroalcoholic extract from Amburana cearensis in 
rats. Pharm. Biol., v.41, n.4, p.308-314, 2003b.
LEAL, L.K.; PIERDONÁ, T.M.; GÓES, J.G.; FONSÊCA, K.S.; 
CANUTO, K.M.; SILVEIRA, E.R.; BEZERRA, A.M.; 
VIANA, G.S. A comparative chemical and pharmacological 
study of standardized extracts and vanillic acid from 
wild and cultivated Amburana cearensis. A.C. Smith. 
Phytomedicine, v.18, n.2, p.230-233, 2010.
MEGA, T.P.; SANTOS, P.M.; SOUZA-MACHADO, A.; 
NOBLAT, L.A.B.C.; CRUZ, A.A. Use of medicinal herbs 
by patients with severe asthma managed at a referral center. 
Braz. J. Pharm. Sci., v.47, n.3, p.643-649, 2011.
METCALFE, A.; WILLIAMS, J.; MCCHESNEY, J.; PATTEN, 
S.B.; JETTÉ, N. Use of complementary and alternative 
medicine by those with a chronic disease and the general 
population - results of a national population based survey. 
BMC Complement. Altern. Med., v.10, p.1-6, 2010.
PASSALACQUA, G.; COMPALATI, E.; SCHIAPPOLI, M.; 
SENNA, G. Complementary and alternative medicine for 
the treatment and diagnosis of asthma and allergic diseases. 
Monaldi Arch. Chest. Dis., v.63, n.1, p.47-54, 2005.
PATEL, Y.A.; PATEL, P.; BAVADIA, H.; DAVE, J.; TRIPATHI, 
C.B. A randomized, open labeled, comparative study to 
assess the efficacy and safety of controller medications as 
add on to inhaled corticosteroid and long-acting β2 agonist 
in the treatment of moderate-to-severe persistent asthma. J. 
Postgrad. Med., v.56, n.4, p.270-274, 2010.
SOARES, A.K.A.; SAMPAIO, I.L.; BEZERRA, F.A.F.; 
MORAES, M.O.; MORAES, M.E.A. Clinical toxicology 
study of a herbal medicine formulation of Torresea 
cearensis in healthy volunteers. Rev. Bras. Plantas Med., 
v.9, n.2, p.55-60, 2007.
TANAKA, A.S.; SAMPAIO, M.U.; MARANGONI, S.; 
OLIVEIRA, B.; NOVELLO, J.C.; OLIVA, M.L., FINK, 
E,; SAMPAIO, C.A. Purification and primary structure 
determination of a Bowman-Birk trypsin inhibitor from 
Torresea cearensis seeds. Biol. Chem., v.378, n.3, p.273-
281, 1997.
Efficacy and safety of cumaru syrup as complementary therapy in mild persistent asthma: a double-blind, randomized, placebo-controlled study 637
THOMAS, M.; SHERAN, J.; SMITH, N.; FONSECA, S.; LEE, 
A.J. AKL1, a botanical mixture for the treatment of asthma: 
a randomized, double-blind, placebo-controlled, cross-over 
study. BMC Pulm. Med., v.7, n.4, p.1-10, 2007.
WONG, E.L.; SUNG, R.Y.; LEUNG, T.F.; WONG, Y.O.; LI, 
A.M.; CHEUNG, K.L.; WONG, C.K.; FOK, T.F.; LEUNG, 
P.C. Randomized, double-blind, placebo-controlled trial 
of herbal therapy for children with asthma. J. Altern. 
Complement Med., v.15, n.10, p.1091-1097, 2009.
WORLD HEALTH ORGANIZATION - WHO guidelines on 
safety monitoring of herbal medicines in pharmacovigilance 
systems [serial online], 2004 Available at: <http://apps.
who.int/medicinedocs/index/assoc/s7148e/s7148e.pdf>. 
Acessed on: 13 jun. 2011.
ZHOU, T.N.; TANG, L.H.; HUANG, S.C.; LU, D.D.; WANG, 
Y.; LIU, L.F.; LAI, P.; YE, M.R. Study on the antitussive 
and antiasthmatic effects of Radix Fici Hirtae. Zhong. Yao 
Cai, v.32, n.4, p.571-574, 2009.
Received for publication on 18th March 2012
Accepted for publication on 19th July 2012
